Fortress Biotech Inc (FBIO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

2 GANSEVOORT STREET NEW YORK, NY 10014

Bio-pharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.

Data as of 2020-08-01
Market Cap228.866 Million Shares Outstanding82.474 Million Avg 30-day Volume972.086 Thousand
P/E Ratio Dividend Yield EPS-0.92
Price/Sales6.767 Price cash flow ratio Price free cash flow ratio-3.0
Book Value0.45 Price to Tangible Book7.59 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.129986
BETA2.13723 52-week High/Low3.45 / 1.04 Stddev0.255048
View SEC Filings from FBIO instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 56 18 (1.18%)
Aggregate 13F shares on 03/31/2020: 13.019 Million 10.475 Million
Aggregate 13F shares on 12/31/2019: 6.883 Million 5.032 Million
Percent change: 89.16% 108.17%
Funds creating new positions: 13 3
Funds Adding to an existing position: 19 7
Funds closing out their position: 10 4
Funds reducing their position: 9 5
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding FBIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FBIO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WEISS MICHAEL S CEO AND PRESIDENT

  • Officer
  • Director
14,434,214 2020-06-22 1

ROWINSKY ERIC K

  • Director
0 2020-06-16 1

ROSENWALD LINDSAY A MD

  • Director
262,280 2020-06-05 0

ROGERS MICHAEL W

38,629 2020-06-05 0

LU LUCY PRESIDENT, CEO

  • Officer
  • Director
0 2020-02-12 0

HOENLEIN MALCOLM

  • Director
385,000 2020-01-01 1

LOBELL J JAY

  • Director
1,036,000 2020-01-01 1

KLEIN DOV

  • Director
555,000 2020-01-01 1

HARVEY JIMMIE

  • Director
650,000 2020-01-01 1

LORENZ KEVIN

  • Director
164,582 2020-01-01 2

HUNTER ROBYN CHIEF FINANCIAL OFFICER

  • Officer
220,619 2019-06-03 0

COOPER GLENN L MD

  • Director
35,709 2019-05-23 0

AVGERINOS GEORGE SVP, BIOLOGICS OPERATIONS

  • Officer
655,170 2018-12-11 0

SANDAGE BOBBY W. JR., PHD.

  • Director
0 2018-06-20 0

RITTER DALE VICE PRESIDENT, FINANCE

  • Officer
19,827 2017-09-14 0

BARRETT DAVID JONATHAN SEE REMARKS

  • Officer
0 2017-03-29 0

BEERMAN NOAH D SEE REMARKS

  • Officer
0 2011-09-26 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments